Aripiprazole: a new treatment for schizophrenia

Author: Bourin, Michel1

Source: Future Neurology, Volume 1, Number 4, July 2006 , pp. 373-388(16)

Publisher: Future Medicine

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

Aripiprazole has a unique mechanism of action that differs from all currently available antipsychotic agents. Aripiprazole combines potent partial agonist activity at dopamine D2 receptors and serotonin (5-HT)1A receptors, with antagonist activity at 5-HT2A receptors. In short-term clinical studies, aripiprazole produced significant improvements in Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impression (CGI) Scale efficacy scores from baseline compared with placebo. These improvements were similar to those observed with haloperidol and risperidone. Aripiprazole has a rapid onset of efficacy, with improvements in PANSS total and positive subscale scores and CGI severity of illness scores seen as early as 1 week after starting treatment. Aripiprazole's efficacy is maintained in long-term treatment following acute relapse in patients with schizophrenia. In the 52-week maintenance of response study, completion and responder rates were significantly higher with aripiprazole treatment compared with haloperidol, and aripiprazole was superior to haloperidol in treating negative and associated depressive symptoms. Short- and long-term clinical studies show that aripiprazole has a low liability for extrapyramidal side effects and does not increase the risk of weight gain, hyperprolactinemia, QTcprolongation, somnolence, glucose intolerance or lipid dysregulation. Patients with schizophrenia or schizoaffective disorder can be switched safely and effectively to aripiprazole from their existing antipsychotic medication using any one of three strategies.

Keywords: antipsychotic; aripiprazole; dopamine partial agonist

Document Type: Drug Evaluation

DOI: 10.2217/14796708.1.4.373

Affiliations: 1: EA 3256 Neurobiologie de l'Anxiété et de la Dépression, Faculté de Médecine, 1 rue Gaston Veil, BP 53508, 44035 Nantes Cedex 01, France., Email: michel.bourin@univ-nantes.fr

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$73.00 plus tax

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A